Filing Details
- Accession Number:
- 0001214659-21-001205
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-03 17:09:12
- Reporting Period:
- 2021-02-02
- Accepted Time:
- 2021-02-03 17:09:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1673528 | Daniel Faga | C/O Mirati Therapeutics 9393 Towne Centre Drive Suite 200 San Diego CA 92121 | Evp, Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-02-02 | 1,340 | $114.33 | 31,978 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-02-02 | 1,340 | $194.38 | 30,638 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non Qualified Stock Option (right to buy) | Disposition | 2021-02-02 | 1,340 | $0.00 | 1,340 | $114.33 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
63,630 | 2030-01-05 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
- 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.